Edmond DE Rothschild Holding S.A. Acquires Shares of 875,810 Boston Scientific Corporation $BSX

Edmond DE Rothschild Holding S.A. acquired a new stake in Boston Scientific Corporation (NYSE:BSX) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 875,810 shares of the medical equipment provider’s stock, valued at approximately $37,380,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BSX. Kelleher Financial Advisors acquired a new position in Boston Scientific in the second quarter valued at approximately $25,000. FWL Investment Management LLC purchased a new stake in Boston Scientific in the 2nd quarter worth approximately $26,000. Swiss RE Ltd. acquired a new stake in shares of Boston Scientific during the 4th quarter worth approximately $26,000. Garton & Associates Financial Advisors LLC purchased a new position in shares of Boston Scientific during the 4th quarter valued at approximately $26,000. Finally, Clal Insurance Enterprises Holdings Ltd purchased a new position in shares of Boston Scientific during the 1st quarter valued at approximately $28,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Stock Up 3.1%

NYSE BSX opened at $52.02 on Thursday. The business has a fifty day moving average price of $46.22 and a 200 day moving average price of $58.22. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. The company has a market cap of $75.39 billion, a P/E ratio of 21.06, a P/E/G ratio of 1.10 and a beta of 0.56. Boston Scientific Corporation has a one year low of $42.20 and a one year high of $109.50.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.83 by $0.03. The company had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm’s quarterly revenue was up 7.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Research analysts anticipate that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific announced that its Board of Directors has initiated a stock buyback plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s leadership believes its shares are undervalued.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Needham & Company LLC decreased their target price on shares of Boston Scientific from $77.00 to $57.00 and set a “buy” rating for the company in a research note on Wednesday, July 8th. Jefferies Financial Group cut their price objective on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating for the company in a report on Wednesday, June 24th. Bank of America dropped their target price on Boston Scientific from $105.00 to $68.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Evercore set a $65.00 price target on Boston Scientific in a research note on Monday, July 6th. Finally, Citigroup reduced their price target on Boston Scientific from $70.00 to $61.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Twenty-four analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $71.62.

Insider Buying and Selling

In related news, Director David C. Habiger bought 2,100 shares of the stock in a transaction dated Wednesday, August 5th. The shares were acquired at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the acquisition, the director directly owned 17,160 shares in the company, valued at approximately $816,644.40. This trade represents a 13.94% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael F. Mahoney purchased 186,240 shares of the company’s stock in a transaction dated Monday, August 3rd. The stock was bought at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the transaction, the chief executive officer directly owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. This represents a 13.27% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last three months, insiders have acquired 194,522 shares of company stock worth $9,385,210. 0.34% of the stock is owned by insiders.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.